Cargando…

Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features

Per- and polyfluoroalkyl substances (PFAS) are endocrine disrupting chemicals which could be associated with cancer development, such as kidney and testicular cancers, pancreatic and hepatocellular carcinoma and thyroid tumor. Available scientific literature offers no information on the role of PFAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Fiore, Paolo, Cavallin, Francesco, Mazza, Marcodomenico, Benna, Clara, Monico, Alessandro Dal, Tadiotto, Giulia, Russo, Irene, Ferrazzi, Beatrice, Tropea, Saveria, Buja, Alessandra, Cozzolino, Claudia, Cappellesso, Rocco, Nicolè, Lorenzo, Piccin, Luisa, Pigozzo, Jacopo, Chiarion-Sileni, Vanna, Vecchiato, Antonella, Menin, Chiara, Bassetto, Franco, Tos, Angelo Paolo Dei, Alaibac, Mauro, Mocellin, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743017/
https://www.ncbi.nlm.nih.gov/pubmed/36482443
http://dx.doi.org/10.1186/s12940-022-00944-x
_version_ 1784848644002807808
author Del Fiore, Paolo
Cavallin, Francesco
Mazza, Marcodomenico
Benna, Clara
Monico, Alessandro Dal
Tadiotto, Giulia
Russo, Irene
Ferrazzi, Beatrice
Tropea, Saveria
Buja, Alessandra
Cozzolino, Claudia
Cappellesso, Rocco
Nicolè, Lorenzo
Piccin, Luisa
Pigozzo, Jacopo
Chiarion-Sileni, Vanna
Vecchiato, Antonella
Menin, Chiara
Bassetto, Franco
Tos, Angelo Paolo Dei
Alaibac, Mauro
Mocellin, Simone
author_facet Del Fiore, Paolo
Cavallin, Francesco
Mazza, Marcodomenico
Benna, Clara
Monico, Alessandro Dal
Tadiotto, Giulia
Russo, Irene
Ferrazzi, Beatrice
Tropea, Saveria
Buja, Alessandra
Cozzolino, Claudia
Cappellesso, Rocco
Nicolè, Lorenzo
Piccin, Luisa
Pigozzo, Jacopo
Chiarion-Sileni, Vanna
Vecchiato, Antonella
Menin, Chiara
Bassetto, Franco
Tos, Angelo Paolo Dei
Alaibac, Mauro
Mocellin, Simone
author_sort Del Fiore, Paolo
collection PubMed
description Per- and polyfluoroalkyl substances (PFAS) are endocrine disrupting chemicals which could be associated with cancer development, such as kidney and testicular cancers, pancreatic and hepatocellular carcinoma and thyroid tumor. Available scientific literature offers no information on the role of PFAS in melanoma development/progression. Since 1965, a massive environmental contamination by PFAS has occurred in northeastern Italy. This study compared histopathology and prognosis between melanoma patients exposed (n = 194) and unexposed (n = 488) to PFAS. All patients were diagnosed and/or treated for melanoma at the Veneto Oncological Institute and the University Hospital of Padua (Italy) in 1998–2014. Patients were categorized in exposed or unexposed groups according to their home address and the geographical classification of municipalities affected by PFAS contamination as provided by Veneto Government in 2018. Presence of mitoses was found in 70.5% of exposed patients and 58.7% of unexposed patients (p = 0.005). Median follow-up was 90 months (IQR 59–136). 5-year overall survival was 83.7% in exposed patients and 88.0% in unexposed patients (p = 0.20); 5-year disease-specific survival was 88.0% in exposed patients and 90.9% in unexposed patients (p = 0.50); 5-year disease-free survival was 83.8% in exposed patients and 87.3% in unexposed patients (p = 0.20). Adjusting for imbalanced characteristics at baseline (presence of mitoses), survival was not statistically different between exposed and unexposed patients (overall survival: HR 1.10, 95% CI 0.77 to 1.58, p = 0.57; disease-specific survival: HR 0.99, 95% CI 0.62 to 1.59, p = 0.99; disease-free survival: HR 1.10, 95% CI 0.74 to 1.64, p = 0.62). Although the magnitude of PFAS exposure was not quantifiable, our findings suggested that exposure to PFAS was associated with higher level of mitosis in melanoma patients, but this did not translate into a survival difference. Further studies are required to investigate this relationship and all effects of PFAS on prognosis.
format Online
Article
Text
id pubmed-9743017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97430172022-12-13 Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features Del Fiore, Paolo Cavallin, Francesco Mazza, Marcodomenico Benna, Clara Monico, Alessandro Dal Tadiotto, Giulia Russo, Irene Ferrazzi, Beatrice Tropea, Saveria Buja, Alessandra Cozzolino, Claudia Cappellesso, Rocco Nicolè, Lorenzo Piccin, Luisa Pigozzo, Jacopo Chiarion-Sileni, Vanna Vecchiato, Antonella Menin, Chiara Bassetto, Franco Tos, Angelo Paolo Dei Alaibac, Mauro Mocellin, Simone Environ Health Research Per- and polyfluoroalkyl substances (PFAS) are endocrine disrupting chemicals which could be associated with cancer development, such as kidney and testicular cancers, pancreatic and hepatocellular carcinoma and thyroid tumor. Available scientific literature offers no information on the role of PFAS in melanoma development/progression. Since 1965, a massive environmental contamination by PFAS has occurred in northeastern Italy. This study compared histopathology and prognosis between melanoma patients exposed (n = 194) and unexposed (n = 488) to PFAS. All patients were diagnosed and/or treated for melanoma at the Veneto Oncological Institute and the University Hospital of Padua (Italy) in 1998–2014. Patients were categorized in exposed or unexposed groups according to their home address and the geographical classification of municipalities affected by PFAS contamination as provided by Veneto Government in 2018. Presence of mitoses was found in 70.5% of exposed patients and 58.7% of unexposed patients (p = 0.005). Median follow-up was 90 months (IQR 59–136). 5-year overall survival was 83.7% in exposed patients and 88.0% in unexposed patients (p = 0.20); 5-year disease-specific survival was 88.0% in exposed patients and 90.9% in unexposed patients (p = 0.50); 5-year disease-free survival was 83.8% in exposed patients and 87.3% in unexposed patients (p = 0.20). Adjusting for imbalanced characteristics at baseline (presence of mitoses), survival was not statistically different between exposed and unexposed patients (overall survival: HR 1.10, 95% CI 0.77 to 1.58, p = 0.57; disease-specific survival: HR 0.99, 95% CI 0.62 to 1.59, p = 0.99; disease-free survival: HR 1.10, 95% CI 0.74 to 1.64, p = 0.62). Although the magnitude of PFAS exposure was not quantifiable, our findings suggested that exposure to PFAS was associated with higher level of mitosis in melanoma patients, but this did not translate into a survival difference. Further studies are required to investigate this relationship and all effects of PFAS on prognosis. BioMed Central 2022-12-09 /pmc/articles/PMC9743017/ /pubmed/36482443 http://dx.doi.org/10.1186/s12940-022-00944-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Del Fiore, Paolo
Cavallin, Francesco
Mazza, Marcodomenico
Benna, Clara
Monico, Alessandro Dal
Tadiotto, Giulia
Russo, Irene
Ferrazzi, Beatrice
Tropea, Saveria
Buja, Alessandra
Cozzolino, Claudia
Cappellesso, Rocco
Nicolè, Lorenzo
Piccin, Luisa
Pigozzo, Jacopo
Chiarion-Sileni, Vanna
Vecchiato, Antonella
Menin, Chiara
Bassetto, Franco
Tos, Angelo Paolo Dei
Alaibac, Mauro
Mocellin, Simone
Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title_full Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title_fullStr Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title_full_unstemmed Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title_short Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
title_sort per- and polyfluoroalkyl substances (pfas) exposure in melanoma patients: a retrospective study on prognosis and histological features
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743017/
https://www.ncbi.nlm.nih.gov/pubmed/36482443
http://dx.doi.org/10.1186/s12940-022-00944-x
work_keys_str_mv AT delfiorepaolo perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT cavallinfrancesco perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT mazzamarcodomenico perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT bennaclara perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT monicoalessandrodal perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT tadiottogiulia perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT russoirene perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT ferrazzibeatrice perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT tropeasaveria perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT bujaalessandra perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT cozzolinoclaudia perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT cappellessorocco perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT nicolelorenzo perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT piccinluisa perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT pigozzojacopo perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT chiarionsilenivanna perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT vecchiatoantonella perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT meninchiara perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT bassettofranco perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT tosangelopaolodei perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT alaibacmauro perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures
AT mocellinsimone perandpolyfluoroalkylsubstancespfasexposureinmelanomapatientsaretrospectivestudyonprognosisandhistologicalfeatures